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Abstract
Background—Little is known about the association of eating disorder (ED) subtypes across
multiple categories of substance use (SU) in population-based samples. We examined the association
between EDs and SU in a large population-based sample.
Method—Female participants (N=13,297) were from the Swedish Twin Registry (Lichtenstein et
al., 2006). SU was examined in four defined groups − (1) anorexia nervosa (AN); (2) bulimia nervosa
(BN); (3) anorexia nervosa and bulimia nervosa (ANBN); and (4) binge eating disorder (BED) as
well as a referent group without EDs (no ED). Secondary analyses examined differences between
restricting AN (RAN) and binge and/or purge AN (ANBP).
Results—In general, EDs were associated with greater SU relative to the referent. The AN group
had significantly increased odds for all illicit drugs. Significant differences emerged across the RAN
and ANBP groups for alcohol abuse/dependence, diet pills, stimulants, and polysubstance use with
greater use in the ANBP group. Across ED groups, (1) the BN and ANBN groups were more likely
to report alcohol abuse/dependence relative to the AN group, (2) the ANBN group was more likely
to report diet pill use relative to the AN, BN, and BED groups, and (3) the BN group was more likely
to report diet pill use relative to the no ED, AN and BED groups.
Conclusions—EDs are associated with a range of SU behaviors. Improved understanding of how
they mutually influence risk could enhance understanding of etiology and prevention.
Introduction
Approximately 50% of individuals with an eating disorder (ED) abuse or are dependent on
alcohol or illicit substances compared with approximately 9% of the general population
(Holderness et al., 1994; The National Center on Addiction and Substance Abuse (CASA at
Columbia University, 2003). Of individuals with a substance use disorder, more than 35%
report some form of an ED (CASA, 2003) compared to lifetime prevalence estimates of
approximately 5% for women in the United States (Hudson et al., 2007). While it has been
established that the co-occurrence between EDs and substance use (SU) exists, prevalence
varies markedly across studies (Holderness et al., 1994), which is partially attributable to study
design and methodology. Most studies have not compared SU across the various subtypes of
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EDs often due to small sample sizes, particularly for anorexia nervosa (AN). Additionally,
most research on EDs and SU has focused on alcohol, tobacco, or broadly defined illicit drug
use. Finally, few studies include a non-ED control group, which is necessary in order to make
meaningful comparisons between those with and without an ED.
Substances associated with EDs include alcohol, tobacco, cannabis, cocaine, heroin, and
amphetamines (Blinder et al., 2006; Bulik et al., 2004a; Bulik et al., 2004b; Root et al., in
press; CASA, 2003) and patterns of association vary across ED subtypes. Those who endorse
binge eating, including those with bulimia nervosa (BN) and a lifetime history of both anorexia
nervosa and bulimia nervosa (ANBN), tend to exhibit higher levels of licit and illicit drug use
(Herzog et al., 1992; Hudson et al., 2007; Root et al., in press; Ross & Ivis, 1999; CASA,
2003; Wiederman & Pryor, 1996), including use of diet pills (Reba-Harrelson et al., 2008),
than individuals with AN or no ED. For example, females with purging symptoms are more
likely to report frequent alcohol use and binge drinking than females without ED symptoms
(Adams & Araas, 2006). Conversely, females who report alcohol problems and/or binge
drinking were more likely to report recent ED symptoms (Field et al., 2002; CASA, 2003;
Wiederman & Pryor, 1996). Further, research suggests that those with BN and those with
ANBN have a higher prevalence of lifetime alcohol abuse and/or dependence than individuals
with AN (Bulik et al., 2004c). However, of those with AN, there is higher prevalence of alcohol
abuse and/or dependence in the binge and/or purge subtype of anorexia nervosa (ANBP) than
restricting anorexia nervosa (RAN; (Blinder et al., 2006). Finally, those with BN are also more
likely to report illicit drug use, particularly amphetamines, barbiturates, marijuana,
tranquilizers, and cocaine (CASA, 2003), with the heaviest illicit drug use found among
females who binge and purge.
Tobacco use is also more common among individuals with EDs compared to those without
(Anzengruber et al., 2006) and, as with alcohol, patterns of use vary across ED category and
subtype. Anzengruber and colleagues (2006) found that women with BN or ANBP had a higher
prevalence of cigarette use compared to women with RAN, who had a similar prevalence as
women without an ED. Although cigarettes are the most studied form of tobacco, cigarette use
in Sweden appears to be declining while tobacco use remains constant (Furberg et al., 2006;
Wersall & Eklund, 1998). This is partly attributable to the increased use of snus, a form of oral
smokeless tobacco that has been popular in Sweden for decades, particularly among men
(Furberg et al., 2006), and has recently been test marketed in the United States. Snus is a less
harmful and more discreet form of tobacco (Lagergren et al., 2000; Lewin et al., 1998;
Osterdahl et al., 2004) and thus may be a more appealing tobacco product. However, to date,
no published data have been reported on snus use among those with an ED.
Most research on SU and EDs has focused on either BN or broadly defined AN with few studies
comparing SU across subtypes of AN. Root and colleagues (Root et al., in press) examined
SU across several AN subtypes and reported differences in prevalence of substance use disorder
across AN subtypes, with more in the ANBN group reporting a substance use disorder than
those in the RAN and purging AN groups supporting previous research (Eddy et al., 2002).
Root et al. (Root et al., in press) also report that cannabis was the most frequently used substance
by women with AN, including the RAN group, and that individuals who purged were more
likely to report SU than those who did not purge. Although informative, this sample was
collected for a study of the genetics of EDs which recruited male and female probands affected
with AN. The present study explores these issues in depth in a population-based sample.
The purpose of this study was to extend previous research by examining the prevalence of SU
behaviors across ED groups relative to individuals with no history of EDs in a large population-
based female sample. Specifically, we: (1) compared the prevalence of SU across four ED
groups relative to a non-ED referent; (2) determined whether SU, and specifically, which
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substances, are more common in those with ANBP compared to RAN; (3) investigated the
prevalence of snus use across ED groups; and (4) conducted pairwise comparisons for each
substance across EDs groups to determine which groups report significantly more SU and to
also report effect sizes for significant comparisons. Our approach focuses on lifetime history
for both EDs and SU. Lifetime use models are a necessary first step in the advancement to
more complex models assessing casual mechanisms (Eaves et al., 2004; Kendler & Prescott,
1999). For example, the ultimate liability to alcohol dependence in an individual who has never
been exposed to alcohol is unknown. Thus, lifetime use is an important variable for any
substance because it is a necessary first step in the path of developing abuse or dependence.
Method
Participants
Participants were drawn from the Screening Twin Adults: Genes and Environment (STAGE)
cohort of the Swedish Twin Registry [(STR; (Lichtenstein et al., 2006), a large population-
based prospective sample of Swedish twins born 1959–1985 (Lichtenstein et al., 2006). Using
web-based questionnaires, (or computer assisted telephone interviews for those preferring this
method), data were collected on most common complex diseases including information on EDs
and SU. Kappa values were calculated for several components and based on 100 respondents
who were first tested using the web-based questionnaire and then retested 2–5 months later
using the computer assisted telephone interview for the purpose of assessing test-retest
reliability across the two methods. Kappa for the ED section was .76 and for the SU section
was .66 suggesting agreement between the web-based questionnaire and the telephone
interview. The current study consisted of a total of 13,297 female participants; males were not
included given low prevalence of EDs
Measures
Eating Disorder Diagnosis—Lifetime history of broadly defined EDs was assessed using
an expanded, on-line Structured Clinical Interview for DSM-IV (SCID) based instrument
designed to collect detailed information about course and severity of EDs. Due to low
prevalence using narrow definitions, we focused on broadly defined ED groups.
Table I presents criteria used to define ED groups. For the primary analyses, participants were
classified into one of five groups based on lifetime history of EDs: (1) no ED; (2) AN; (3) BN;
(4) ANBN; and (5) binge eating disorder (BED). For secondary analyses, the AN group was
subdivided into RAN and ANBP.
Substance Use—Eighteen SU items from the SCID were included. Information on abuse/
dependence was available only for alcohol. Thus, all items were based on use (not abuse or
dependence) with the exception of alcohol abuse/dependence which required the Diagnostic
and Statistical Manual, 4th edition criteria for either abuse or dependence [DSM-IV; (American
Psychiatric Association, 2000)]. Binge drink was defined as either 4 or more bottles of beer, 4
or more glasses of wine (>60 cl), or 3 or more shots of liquor (>18 cl) at one time. Occasional
smoker was defined as smoking less than one cigarette per day on average but more than just
having tried a cigarette and includes those who report only smoking on weekends. Regular
smoker was defined as ever having smoked at least once per day. Occasional snus was defined
as more than just trying snus but less than once per day on average. Regular snus was using
snus at least once per day. Diet pills-weekly was defined as over-the-counter and prescription
diet pill use at least once per week. The remaining SU items cannabis, hallucinogens,
opioids, sedatives, and stimulants - were categorized based on two criteria: (1) lifetime use,
and (2) used more than 10 times per month. Two variables for each substance were created
(e.g., cannabis 10x/month; cannabis-ever). Due to low prevalence, diet pills-ever and
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hallucinogens 10x/month were dropped from the analyses. Polysubstance 10x/month was
defined as having used at least two illicit substances at least 10x/month. Polysubstance-ever
was defined as ever having tried at least two illicit substances.
Statistical Analyses
Prevalence was calculated for the ED groups and the referent across all SU measures. Logistic
regression analyses were conducted using generalized estimating equations (GEE) with PROC
GENMOD to test for statistically significant differences in SU across ED groups. GEE allows
for the correlated nature of the twin data to be controlled. Comparisons for each substance
across pairs of EDs groups (e.g., AN, BN) were conducted to determine which ED groups
reported significantly more SU and to report their associated effect sizes (i.e., odds ratios). In
order to assess differences in SU within the AN group, secondary logistic regression analyses
were conducted to compare the RAN and ANBP subgroups. Given that there were 18 tests
(one for each SU variable), p-values were adjusted using the method of false discovery rate
[FDR; (Benjamini & Hochberg, 1995)], which controls for the expected proportion of Type I
errors (i.e., rejecting the null hypothesis when it is true). It is the expected proportion of false
positives (Type I) among all rejected hypotheses (Type I and Type II) at the desired significance
level. For example, in our study an FDR cutoff of 0.05 was selected, implying that we allowed
one expected false positive out of 20. All analyses were performed using SAS 9.1 (SAS Institute
Inc., 2004).
Results
Ninety-four percent of the sample reported no history of an ED), 3% reported AN (RAN:
n=197, ANBP:n=181), 2% BN, 1% ANBN, and < 1% BED (Table II).
Demographics
Table II presents demographic information across the ED groups and the referent group.
Participants ranged in age from 20 to 47 years with a mean age of 34 years (SD = 7.66). Mean
for highest lifetime adult BMI was greatest among the BED group and mean for lowest lifetime
adult BMI was lowest among the ANBN group.
Prevalence of Substance Use across Eating Disorder Groups
Table III presents prevalence estimates of SU across the groups and provides odds ratios for
statistically significant pairwise comparisons across ED subtypes. Due to space limitations,
we only present the statistically significant pairwise comparisons, however, a complete list of
all 130 pairwise comparisons can be found in the supplementary material.
Overall, statistically significant differences for prevalence across groups were found for
alcohol abuse/dependence, diet pills-weekly, cannabis 10x/month, cannabis-ever,
hallucinogens-ever, opioids 10x/month, opioids-ever, sedatives 10x/month, sedatives-ever,
stimulants 10x/month, stimulants-ever, polysubstance 10x/month and polysubstance-ever. No
statistically significant differences across groups were found for binge drink, occasional
smoker, regular smoker, occasional snus, and regular snus.
Alcohol—The prevalence of alcohol abuse/dependence differed across groups with the AN,
BN, and ANBN groups more likely to have had alcohol abuse/dependence relative to the
referent. Across ED groups (not relative to the referent), the BN and ANBN groups were more
likely to have had alcohol abuse/dependence relative to the AN group. No statistically
significant group differences emerged for prevalence of binge drink.
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Tobacco—No statistically significant group difference emerged for regular smoker,
occasional smoker, occasional snus or regular snus.
Diet Pills—A statistically significant difference across groups was found for diet pills-
weekly. The AN, BN, and ANBN groups were more likely to use diet pills-weekly relative to
the referent. Across ED groups (not relative to the referent), (1) the ANBN group was more
likely to use diet pills-weekly relative to the AN, BN, and BED groups, and (2) the BN group
was more likely to use diet pills-weekly relative to the AN and BED groups.
Illicit Drugs
Cannabis—Statistically significant group differences were found for cannabis 10x/month
and cannabis-ever. Individuals in the AN and BN groups were more likely to use cannabis
10x/month relative to the referent. Those in the AN, BN, ANBN, and BED groups were more
likely to use cannabis-ever relative to the referent.
Hallucinogens—Statistically significant group differences emerged for the hallucinogens-
ever item with the AN group more likely to use hallucinogens-ever relative to the referent.
Opioids—There was a statistically significantly difference across groups for opioids 10x/
month and opioids-ever. Individuals in the AN group were more likely to use opioids 10x/
month relative to the referent and the AN and BN groups were more likely to use opioids-
ever relative to the referent.
Sedatives—Statistically significantly differences across groups were found for sedatives
10x/month and sedatives-ever. The AN and BN groups were more likely to use sedative 10x/
month relative to the referent, and the AN, BN, ANBN, and BED groups were more likely to
use sedatives-ever relative to the referent.
Stimulants—Across groups, statistically significant differences emerged for stimulants
10x/month and stimulants-ever. The AN group was more likely to use stimulants 10x/month
relative to the referent. Those in the AN and BN groups were more likely to use stimulants-
ever compared to the referent.
Polysubstance—Statistically significant differences across groups were found for
polysubstance 10x/month and polysubstance-ever. The AN group was more likely to engage
in polysubstance 10x/month relative to the referent, and the AN, BN, and ANBN groups were
more likely to engage in polysubstance-ever relative to the referent.
Secondary Analyses–Substance Use for RAN and ANBP
Prevalence was statistically significantly higher in the ANBP group compared to the RAN
group for alcohol abuse/dependence (15% vs. 9%; p<.05), diet pills-weekly (35% vs. 9%;
p<.01), stimulants-ever (12% vs. 5%; p<.01), and polysubstance-ever(24% vs. 15%; p<.01).
The ANBP group was 1.93 times more likely than the RAN group to have alcohol abuse/
dependence (χ2=4.08, p≤.043; 95% CI: 1.02, 3.66), 5.76 times more likely to use diet pills-
weekly (χ2=38.68, p≤.001; 95% CI: 3.22, 10.31), 2.86 times more likely to endorse stimulants-
ever (χ2=6.87, p≤.009; 95% CI: 1.28, 6.38), and 1.74 times more likely to engage in
polysubstance-ever (χ2=4.40, p≤.036; 95% CI: 1.04, 2.92). No statistically significant
differences emerged for the remaining substances,.
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This study represents the largest and most detailed exploration to date of a wide range of
substance use in EDs in a population-based sample of Swedish women and presents novel
epidemiologic information on EDs and SU. Three broad themes emerged from the analyses.
First, consistent with previous research, the prevalence of SU was higher in all ED groups than
the referent indicating that SU is not limited to any particular ED presentation. Second, in
contrast with previous studies (Anzengruber et al., 2006), tobacco use was not elevated in
women with EDs relative to the referent. Third, the observation that women with AN report
elevated SU behaviors challenges previously held beliefs that SU is uncommon in women with
AN (Herzog et al., 2006; Wiederman & Pryor, 1996) and the finding that the RAN and ANBP
subgroups differed on alcohol abuse/dependence, weekly diet pill use, stimulant use, and
polysubstance use adds to the literature examining SU across varying presentations of AN.
Although no differences in prevalence emerged for binge drinking across the ED groups
relative to the referent, those in the AN, BN, and ANBN groups were at increased risk for
alcohol abuse/dependence relative to the referent. Observed prevalence in the BN and ANBN
groups (approximately 22%) is consistent with previous research reporting prevalences of
alcohol abuse or dependence of 25% for BN and 14% for ANBN (Bulik et al., 2004c). These
findings could reflect the elevated relative risk of alcohol use disorders among individuals with
BN compared with AN (Kaye et al., 1996; Kaye et al., 1998). However, follow-up analyses
revealing that those in the ANBP group were at elevated risk relative to the RAN group suggests
that increased risk of alcohol abuse/dependence among those with bulimic symptoms or
personality traits such as impulsivity (Bulik et al., 2004c) may also be particular risk factors
for the binge/purge subtype of AN. One possible explanation is that SU may reflect attempts
to reduce negative affect (i.e., shame and guilt) associated with bingeing and purging (Stice &
Shaw, 2002).
For the AN group, additional hypotheses exist. One possible explanation is that the reinforcing
efficacy of alcohol and other drugs is enhanced by the food deprivation associated with the
illness (Bulik et al., 2004c; Carroll & Meisch, 1984). Additionally, alcohol (and drug) use may
assist with the regulation of affect including prominent anxiety symptoms seen in those with
AN (Bulik et al., 2004c; Godart et al., 2000). Overall, our finding of alcohol abuse/
dependence in the AN group, particularly the ANBP group, extends a growing body of
literature supporting SU behaviors among women with AN (Bulik et al., 2004c; Root et al., in
press; von Ranson et al., 2002).
Regarding tobacco use, in contrast to previous research (Anzengruber et al., 2006), we did not
find differences across the groups in cigarette use or snus use. It is possible that as snus use
increases in the female population in Sweden, differences across groups may become
detectable. It is also possible that tobacco products are being used among women both with
and without an ED as a weight control measure thus resulting in no differences between groups.
Consistent with previous research (Reba-Harrelson et al., 2008; Roerig et al., 2003), diet pill
use was elevated in all ED groups. The ANBN group was at particularly elevated risk (i.e.,
approximately 15 times more likely than the referent). Diet pill use has been associated with
purging, novelty seeking, and several Axis I and Axis II disorders (Reba-Harrelson et al.,
2008) which could explain why both the BN and ANBN groups, who tend to score higher on
measures of novelty seeking (Cassin & von Ranson, 2005; Fernandez-Aranda et al., 2006;
Reba et al., 2005), reported more use than the AN group.
The very high diet pill use in women with ANBN and the greater risk for diet pill use in the
ANBP group compared to the RAN group are consistent with a previous report (Reba-
Harrelson et al., 2008) in which diet pill use was similar across purging BN, ANBN, and ANBP.
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Because we were not able to assess temporal ordering of SU and ED symptoms, it is not known
if the ANBN group used the diet pills during the time of their AN diagnosis, their BN diagnosis,
or throughout both illnesses. We speculate that those with ANBN, who by definition have a
history of low weight, may seek out more extreme weight loss measures than individuals with
BN with no history of AN because they may continue to strive for previously achieved low
weight.
Turning to the use of illicit drugs, all ED groups reported greater use of illicit drugs and
polysubstance use relative to the referent. Similar prevalences across ED groups for cannabis-
ever, hallucinogens-ever, stimulants-ever support previous research (Root et al., in press;
Wiederman & Pryor, 1996). Additionally, the BN and ANBN groups had higher risk for several
illicit substances including cannabis, opioids, sedatives, and stimulants, which supports
previous research (Herzog et al., 2006; Hudson et al., 2007; CASA, 2003), as well as for
polysubstance-ever.
Unexpectedly, the AN group was at increased risk for all illicit drug use categories and
polysubstance-ever relative to the referent indicating that drug use is of concern across all ED
subtypes (von Ranson et al., 2002). Extending the AN findings further, AN subtype
comparisons revealed that stimulants-ever was the only illicit substance that was more
frequently reported in the ANBP group relative to the RAN group, adding to the literature
suggesting that illicit drug use is not limited to those with binge eating or purging subtypes of
AN. The attraction of stimulant use in the AN group might in part rest with their appetite
suppressant and increased metabolic effects (Hsieh et al., 2005; Hudson et al., 1992;
Wiederman & Pryor, 1996) and the attraction of cannabis and sedatives for their sedating
effects (Swinbourne & Touyz, 2007)
One possible explanation for increased polysubstance use in those with EDs is the association
between polysubstance use and impulsivity (Steiger & Bruce, 2007) and novelty-seeking
(Conway et al., 2003) which is also elevated in individuals with EDs, particularly BN. Because
individuals with polysubstance use have high rates of psychiatric comorbidity (Lynskey et
al., 2006) and often relapse after substance abuse treatment (Marshall, 1994), replication and
additional attention to polysubstance use with ED populations is warranted.
Findings that illicit drug use is occurring across ED groups support a study in which greater
pathological eating behavior was associated with not just alcohol and tobacco but also cannabis
use and other illicit substances (Ross & Ivis, 1999). It is possible these findings can be explained
given genetic research associating family history (Lachman, 2006) to both SU and EDs (Bulik
et al., 2006; Bulik et al., 2007; Pinheiro et al., 2006; Slof-Op ’t Landt et al., 2005). Genetics
influence liability to SU disorder with research suggesting that SU among MZ twin pairs is
two to four times greater compared to DZ twin pairs (Lachman, 2006). Heritability estimates
for alcoholism are often 50% or greater, 40% to 70% for tobacco, and 25% to 80% for other
substances including illicit drugs (Prescott et al., 2006). Regarding EDs, family studies have
demonstrated that both AN and BN tend to be increased in relatives of affected probands
compared to relatives of unaffected probands (Lilenfeld et al., 1998; Pinheiro et al., 2006).
Twin studies have reported heritability estimates between 33% and 84% for AN (Bulik et al.,
2006; Bulik et al., 2007; Slof-Op ’t Landt et al., 2005; Wade et al., 2000) and between 28%
to 83% for BN (Bulik et al., 2000) demonstrating considerable genetic effects for AN and BN.
However, several lines of evidence suggest that EDs and SU might not necessarily be
influenced by shared genetic factors. Kendler and colleagues (Kendler et al., 1995), in a twin
study of six major psychiatric illnesses, did not find a strong genetic association between BN
and alcoholism. Similarly, Lilenfeld and colleagues (1998) concluded that EDs and alcoholism
were not co-transmitted in families. Lastly, Kaye and colleagues (1996) reported that BN and
substance use disorders, including alcohol abuse and dependence, were transmitted
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independently suggesting that women with BN do not have a familial vulnerability to substance
use disorders. In contrast, one study has reported a moderate genetic correlation (ra = 0.39)
between broadly defined BN and drug use disorders (Baker et al., 2007). Additional work is
required including evaluations of both genetic and environmental factors and their interactions
in order to understand both the comorbid profile and familial transmission of EDs and SU.
Limitations
Limitations of our study must be considered. First, results cannot be generalized to other
ancestry groups or to males. Second, because the study was not prospective, causal conclusions
pertaining to the development of either EDs or SU behaviors cannot be discussed. Third,
additional unexamined factors may have influenced findings including factors that may be
associated with EDs and substance use disorders. Of particular relevance is research indicating
that depression/negative affect (Fernandez-Aranda et al., 2007) and/or anxiety (Bulik et al.,
2004c; Godart et al., 2006) are associated with the onset of both EDs and SU. Fourth, one must
consider whether any aspects of a twin population could limit generalizability of the observed
prevalence of SU and EDs to non-twin samples. By virtue of socializing together, twins may
be more likely to be exposed to various substances and behaviors (e.g. one twin’s exposure to
cigarettes could increase the likelihood of the co-twin trying a cigarette). If this were the case,
then we could expect prevalences in twins that are higher than the general population. That
does not appear to be the case in these data as, for example, 11% of our sample was classified
as regular smokers which is below the reported national prevalence of 20% in Swedish females
ages 16–84 (Strong & Bonita, 2003). Nonetheless, correlated exposure among twins and
generalizability to non-twin samples is a potential weakness that must be considered when
interpreting findings. Fifth, for polysubstance use, we only examined whether individuals were
using more than two illicit substances either ever in their lifetime or at least 10 times per month;
we did not examine which substances cluster together across individuals, nor did we include
alcohol or tobacco use in these analyses. Future research would benefit from examining
individuals’ substances of choice for polysubstance drug use in order to understand better
differences in SU involvement across ED groups. Last, the BED group is quite small in our
sample (~4%) which might be due in part to the much lower base rate of obesity in Sweden
compared to the U.S. (Neovius et al., 2006; Ogden et al., 2006). As a result of the small sample,
not all analyses could be conducted with the BED group. Thus, it is important to interpret the
current findings with caution.
Conclusions
Results of this study add to the growing literature on EDs and SU by further emphasizing that
EDs may be associated with a range of SU behavior. The STAGE sample used in the current
study provided extensive EDs and SU phenotyping, including snus use which has never been
reported before. This study represents the first large population-based study that was able to
contrast SU patterns across AN, BN, ANBN, and BED. Moreover, our secondary analyses
allowed us to explore differences within AN subtypes in a non-treatment-seeking sample.
Findings highlight the importance of screening for various types of SU when examining and
treating individuals with disordered eating. Although we cannot examine temporal patterns of
onset, several possibilities exist, namely, the presence of an ED may increase risk for SU, SU
may increase risk for EDs, or a third underlying variable might increase risk for both EDs and
SU. Additional investigations incorporating patterns of onset will assist with determining how
EDs and SU mutually influence risk (Field et al., 2002; Stice & Shaw, 2002). Presenting
comprehensive epidemiologic data in order to characterize the sample fully was a necessary
first step toward more advanced twin methodology exploring the complex genetic and
environmental factors influencing liability to both traits. This is critically important given the
heightened risk for physical complications, including suicide risk, among those with both an
ED and substance use disorder (Franko et al., 2005; Keel et al., 2003).
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Table I
Criteria used for eating disorder diagnosis.
Diagnosis Criteria*/Item
Anorexia nervosa (AN) 1 BMI < 18.55
2 Intense fear of gaining weight
3 Disturbance in the way in which one’s body weight or shape is experienced, undue influence of body weight or
shape on self-evaluation, or denial of the seriousness of the current low body weight
4 Includes either subtype (i.e., restricting AN and binge and/or purge AN)
Bulimia nervosa (BN) 1 Recurrent episodes of binge eating
2 Recurrent inappropriate compensatory behavior in order to prevent weight gain
3 Binge eating and compensatory behaviors occur ≥ 4 times in a month
4 Self-evaluation is unduly influenced by body shape and weight
5 Disturbance does not occur exclusively during episodes of AN
Anorexia nervosa/bulimia
nervosa (ANBN)
Lifetime diagnosis of AN and BN as defined above
Binge eating disorder
(BED)
1 Recurrent binge eating characterized by eating an unusually large amount of food in a discrete period of time, and
having a sense of loss of control
2 Marked distress regarding binge eating
3 Binge eating occurs ≥ 4 times for at least one month (excluded duration of 6 months criteria)
4 Binge eating not associated with compensatory behaviors
Restricting AN (RAN) 1 BMI < 18.55
2 Intense fear of gaining weight
3 Disturbance in the way in which one’s body weight or shape is experienced, undue influence of body weight or
shape on self-evaluation, or denial of the seriousness of the current low body weight
4 No bingeing or purging
Binge and/or purge AN
(ANBP)
1 BMI < 18.55
2 Intense fear of gaining weight
3 Disturbance in the way in which one’s body weight or shape is experienced, undue influence of body weight or
shape on self-evaluation, or denial of the seriousness of the current low body weight
4 Bingeing and/or purging during low weight
*
Based on DSM-IV criteria.
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